Price Alert

(ION)

AMEX: ION · Real-Time Price · USD

35.22

-0.28 (-0.79%)

At close: Sep 02, 2025, 3:55 PM

35.18

-0.10%

After-hours: Sep 02, 2025, 05:05 PM EDT

-0.79% (1D)

Bid	30
Market Cap	2.3M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
EPS (ttm)	1.6777372
PE Ratio (ttm)	20.99
Forward PE	n/a
Analyst	n/a

Ask	35.19
Volume	1,296
Avg. Volume (20D)	2,775
Open	35.03
Previous Close	35.50
Day's Range	34.88 - 35.22
52-Week Range	20.72 - 35.50
Beta	n/a

About ION

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ION

Website n/a

Full Company Profile

News

3 weeks ago · accessnewswire.com

How I-ON Digital and it's Flagship ION.au Stablecoin Align with the National Digital Asset Policy Framework

Setting the Gold Standard for Responsible Digital Finance Under the National Framework CHICAGO, ILLINOIS / ACCESS Newswire / August 6, 2025 / In response to the evolving landscape of digital finance, ...

1 month ago · etftrends.com

Lithium ETFs: Charging Ahead

This summer has brought a renewed focus on alternative assets. Investors are rotating into gold, other precious metals, bitcoin, and option-based strategies.

1 month ago · accessnewswire.com

ION.au: The Gold-Backed Stablecoin Set to Dominate the GENIUS Act Era

CHICAGO, ILLINOIS / ACCESS Newswire / July 22, 2025 / In a digital economy flooded with algorithmic coins and dollar-backed tokens that rely on promises rather than proof, one asset emerges as the mos...

2 months ago · newsfilecorp.com

ION Announces Closing of Debt Settlement and Update on Joint Venture on Urgakh Naran Project

Toronto, Ontario--(Newsfile Corp. - July 3, 2025) - Lithium ION Energy Limited (TSXV: ION) (FSE: Z4A) ("ION" or the "Company") announces that it has closed its previously announced debt settlements wi...

2 months ago · businesswire.com

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluat...